Shanghai Bioxin Biotechnology Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
63
- Stock Symbol
-
02185
- Investments
-
3
- Share Price
-
$0.11
- (As of Friday Closing)
Shanghai Bioxin Biotechnology General Information
Description
Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension. Currently, the portfolio has three product candidates in various stages of clinical development.
Contact Information
Website
www.bio-heart.comCorporate Office
- No. 59 Kaiqing Road, Pudong New Area
- 4th Floor, Building 7
- Shanghai, 201201
- China
Corporate Office
- No. 59 Kaiqing Road, Pudong New Area
- 4th Floor, Building 7
- Shanghai, 201201
- China
Shanghai Bioxin Biotechnology Stock Performance
As of 13-Nov-2026, Shanghai Bioxin Biotechnology’s stock price is $0.11. Its current market cap is $27.9M with 243M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.11 | $0.12 | $0.11 - $1.00 | $27.9M | 243M | 87K | -$0.04 |
Shanghai Bioxin Biotechnology Financials Summary
As of 30-Jun-2026, Shanghai Bioxin Biotechnology has a trailing 12-month revenue of $5.49M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 67,760 | 154,838 | 16,967 | 58,630 |
| Revenue | 5,495 | 6,248 | 0 | 0 |
| EBITDA | (10,415) | (9,886) | (12,012) | (24,154) |
| Net Income | (10,790) | (9,741) | (12,256) | (24,862) |
| Total Assets | 116,395 | 118,982 | 100,516 | 115,382 |
| Total Debt | 1,697 | 1,819 | 1,135 | 249 |
Shanghai Bioxin Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Shanghai Bioxin Biotechnology Patents
Shanghai Bioxin Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240226011-A1 | Core-shell micelle microsphere, and preparation method therefor and use thereof | Pending | 28-Dec-2022 | ||
| EP-4643853-A1 | Core-shell structure micellar microsphere, preparation method therefor, and use thereof | Pending | 28-Dec-2022 | ||
| EP-4643853-A4 | Core-shell structure micellar microsphere, preparation method therefor, and use thereof | Pending | 28-Dec-2022 | ||
| WO-2024138798-A1 | Core-shell structure micellar microsphere, preparation method therefor, and use thereof | Inactive | 28-Dec-2022 | ||
| JP-2025503347-A | Core-shell structured micellar microspheres and preparation method and use thereof | Active | 28-Dec-2022 | A61K9/167 |
Shanghai Bioxin Biotechnology Signals
Shanghai Bioxin Biotechnology Investments & Acquisitions (3)
Shanghai Bioxin Biotechnology’s most recent deal was a Corporate with ContiTech (Diagnostic Equipment) for . The deal was made on 07-Sep-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ContiTech (Diagnostic Equipment) | 07-Sep-2022 | Corporate | Diagnostic Equipment | ||
| Xinzhi Medical | 22-Jun-2022 | Later Stage VC | Therapeutic Devices | ||
| Angio Care China | 23-Sep-2020 | Merger/Acquisition | Other Devices and Supplies |
Shanghai Bioxin Biotechnology ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Shanghai Bioxin Biotechnology Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Angio Care China | Shanghai, China | 2011 |
Shanghai Bioxin Biotechnology FAQs
-
When was Shanghai Bioxin Biotechnology founded?
Shanghai Bioxin Biotechnology was founded in 2014.
-
Where is Shanghai Bioxin Biotechnology headquartered?
Shanghai Bioxin Biotechnology is headquartered in Shanghai, China.
-
What is the size of Shanghai Bioxin Biotechnology?
Shanghai Bioxin Biotechnology has 63 total employees.
-
What industry is Shanghai Bioxin Biotechnology in?
Shanghai Bioxin Biotechnology’s primary industry is Biotechnology.
-
Is Shanghai Bioxin Biotechnology a private or public company?
Shanghai Bioxin Biotechnology is a Public company.
-
What is Shanghai Bioxin Biotechnology’s stock symbol?
The ticker symbol for Shanghai Bioxin Biotechnology is 02185.
-
What is the current stock price of Shanghai Bioxin Biotechnology?
As of 13-Nov-2026 the stock price of Shanghai Bioxin Biotechnology is $0.11.
-
What is the current market cap of Shanghai Bioxin Biotechnology?
The current market capitalization of Shanghai Bioxin Biotechnology is $27.9M.
-
What is Shanghai Bioxin Biotechnology’s current revenue?
The trailing twelve month revenue for Shanghai Bioxin Biotechnology is $5.49M.
-
What is Shanghai Bioxin Biotechnology’s annual earnings per share (EPS)?
Shanghai Bioxin Biotechnology’s EPS for 12 months was -$0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process